San Diego??'s Amplyx Bags $67 Million...

San Diego??'s Amplyx Bags $67 Million to Advance APX001 into Clinical Development

Aug 2, 2017 Read more: BioSpace

August 2, 2017 - Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67 million through a Series C financing led by Sofinnova Venture Partners and including other new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital. Existing investors New Enterprise Associates, RiverVest Venture Partners, 3 5 RiverVest II and BioMed Ventures also participated in the financing.

Start the conversation, or Read more at BioSpace.

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.